IGC
IGC Pharma·AMEX
--
--(--)
--
--(--)
IGC fundamentals
IGC Pharma (IGC) released its earnings on Nov 14, 2025: revenue was 191.00K (YoY -53.64%), missed estimates; EPS was -0.02 (YoY 0.00%), met estimates.
Revenue / YoY
191.00K
-53.64%
EPS / YoY
-0.02
0.00%
Report date
Nov 14, 2025
IGC Earnings Call Summary for Q2,2026
- Key Drug Candidate Progress: IGC 81 reduces agitation in 2 weeks vs. 10 weeks for existing treatments.
- Clinical Trial Expansion: 35 sites across U.S. and Canada with 50% enrollment.
- Cost Management: Divested non-core assets to reduce expenses.
- AI Innovation: MINT-AD predicts Alzheimer's risk using multimodal data.
- 2026 Focus: Complete phase two trial and advance pipeline.
EPS
Actual | -0.05 | -0.09 | -0.035 | -0.03 | -0.02 | -0.02 | -0.02 | -0.02 | ||||||||||||||||||
Forecast | -0.04 | -0.04 | -0.03 | -0.03 | -0.03 | -0.025 | -0.02 | |||||||||||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -125.00% | +12.50% | 0.00% | +33.33% | +33.33% | +20.00% | 0.00% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 300.00K | 204.00K | 295.00K | 272.00K | 412.00K | 257.00K | 328.00K | 191.00K |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 400.00K | 193.00K | 450.00K | 291.00K | 204.00K | 326.00K | 383.00K |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -49.00% | +52.85% | -39.56% | +41.58% | +25.98% | +0.61% | -50.13% |
Earnings Call
You can ask Aime
What is the market's earnings forecast for IGC Pharma next quarter?What is IGC Pharma's gross profit margin?What factors drove the changes in IGC Pharma's revenue and profit?What were the key takeaways from IGC Pharma's earnings call?What does IGC Pharma do and what are its main business segments?Did IGC Pharma beat or miss consensus estimates last quarter?What is IGC Pharma's latest dividend and current dividend yield?What were the key takeaways from IGC Pharma’s earnings call?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
